A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery

Launched by SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. · Mar 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called YZJ-4729 Tartrate Injection to help relieve pain after abdominal surgery. The main goal is to see how effective and safe this injection is for patients who experience moderate to severe pain following their surgery. The trial is still in the planning stages and has not started recruiting participants yet.

To be eligible for the study, participants should be between the ages of 18 and 80, have a certain body weight range, and be able to understand the study and give their consent. They should also be experiencing significant pain after their surgery, with a pain score of 4 or higher on a scale from 0 to 10. However, individuals with certain medical conditions, such as allergies to opioids, severe psychiatric or nervous system disorders, or uncontrolled blood pressure, will not be able to participate. If someone joins the trial, they can expect to receive the YZJ-4729 injection and be monitored for its effects on their pain and overall safety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Be able to understand the study purpose and cooperate with the study procedures of this trial, voluntarily provide written informed consent
• • 2. Body mass index (BMI) ≥18 kg/m2 and ≤28 kg/m2.
• • 3. ASA I - II
• • 4. Experiences a pain intensity rating of moderate to severe acute pain following abdominal surgery, with a pain intensity score of ≥4 on a Numeric Rating Scale (NRS) within 4 hours post-surgery
• Exclusion Criteria:
• • 1. Allergy to opioids and other medications that may be used during the trial.
• • 2. Nervous system disorders (e.g. epilepsy)
• • 3. Psychiatric disorders (e.g. depression)
• • 4. History of difficult airways
• • 5. Random blood glucose ≥11.1 mmol/L
• • 6. Uncontrolled blood pressure \[e.g., hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg)，or hypotension(systolic blood pressure \<90 mmHg)\]
• • 7. Abnormal pulse oxygen saturation (SpO2 \<90 %)
• • 8. Abnormal liver function or renal function
• • 9. Used agents that could affect the analgesic response
• • 10. Used agents that could affect drug metabolism
• • 11. Has previously participated in another YZJ-4729 clinical study